12,978 Shares in Cardlytics, Inc. (NASDAQ:CDLX) Purchased by XTX Topco Ltd

XTX Topco Ltd bought a new stake in shares of Cardlytics, Inc. (NASDAQ:CDLX) during the 2nd quarter, HoldingsChannel.com reports. The institutional investor bought 12,978 shares of the company’s stock, valued at approximately $107,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Quadrature Capital Ltd acquired a new position in shares of Cardlytics during the first quarter valued at approximately $1,906,000. General Equity Holdings LP increased its position in shares of Cardlytics by 31.0% during the 4th quarter. General Equity Holdings LP now owns 624,058 shares of the company’s stock valued at $5,748,000 after purchasing an additional 147,843 shares during the period. Vanguard Group Inc. raised its stake in shares of Cardlytics by 2.7% in the 1st quarter. Vanguard Group Inc. now owns 2,211,595 shares of the company’s stock worth $32,046,000 after buying an additional 57,805 shares in the last quarter. Clear Street Markets LLC acquired a new stake in shares of Cardlytics in the fourth quarter valued at $199,000. Finally, Virtu Financial LLC bought a new position in Cardlytics during the fourth quarter valued at about $219,000. 68.10% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, COO Amit Gupta sold 22,699 shares of the company’s stock in a transaction dated Wednesday, July 24th. The stock was sold at an average price of $8.66, for a total value of $196,573.34. Following the transaction, the chief operating officer now owns 150,569 shares in the company, valued at approximately $1,303,927.54. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, Director Scott A. Hill acquired 40,000 shares of the business’s stock in a transaction that occurred on Monday, August 12th. The stock was acquired at an average cost of $3.58 per share, for a total transaction of $143,200.00. Following the completion of the acquisition, the director now owns 40,000 shares in the company, valued at $143,200. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Amit Gupta sold 22,699 shares of the business’s stock in a transaction dated Wednesday, July 24th. The shares were sold at an average price of $8.66, for a total value of $196,573.34. Following the completion of the transaction, the chief operating officer now owns 150,569 shares in the company, valued at approximately $1,303,927.54. The disclosure for this sale can be found here. Corporate insiders own 4.40% of the company’s stock.

Cardlytics Stock Down 2.8 %

CDLX stock opened at $3.11 on Wednesday. The company has a debt-to-equity ratio of 1.01, a current ratio of 1.77 and a quick ratio of 1.77. The firm has a market capitalization of $151.72 million, a P/E ratio of -0.70 and a beta of 1.68. Cardlytics, Inc. has a 52-week low of $2.89 and a 52-week high of $20.52. The company’s 50 day simple moving average is $4.68 and its 200-day simple moving average is $8.67.

Cardlytics (NASDAQ:CDLX) last announced its earnings results on Wednesday, August 7th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.12. The company had revenue of $69.64 million for the quarter, compared to the consensus estimate of $75.39 million. Cardlytics had a negative net margin of 50.21% and a negative return on equity of 17.96%. The company’s revenue was down 9.2% on a year-over-year basis. During the same period in the previous year, the business earned ($0.57) EPS. As a group, equities research analysts anticipate that Cardlytics, Inc. will post -1.72 EPS for the current year.

Analysts Set New Price Targets

CDLX has been the subject of a number of research analyst reports. Bank of America downgraded shares of Cardlytics from a “neutral” rating to an “underperform” rating and cut their price target for the company from $4.00 to $3.50 in a report on Thursday, August 15th. Northland Securities cut shares of Cardlytics from an “outperform” rating to a “market perform” rating and reduced their target price for the stock from $7.00 to $5.00 in a report on Friday, August 16th. Northland Capmk lowered shares of Cardlytics from a “strong-buy” rating to a “hold” rating in a research report on Friday, August 16th. Craig Hallum downgraded Cardlytics from a “buy” rating to a “hold” rating in a research report on Thursday, August 8th. Finally, Needham & Company LLC cut Cardlytics from a “buy” rating to a “hold” rating in a report on Thursday, August 8th. One research analyst has rated the stock with a sell rating and five have given a hold rating to the stock. According to data from MarketBeat, Cardlytics presently has a consensus rating of “Hold” and a consensus target price of $7.50.

Cardlytics Profile

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.